Temperature-controlled laminar airflow in severe asthma for exacerbation reduction (The LASER Trial): study protocol for a randomised controlled trial

Holgate ST(2006)The mechanisms, diagnosis and management of severe asthma in adults Lancet 368 780-93

Polosa R(2000)Risk factors and costs associated with an asthma attack’ Thorax 55 19-24

Hoskins G(2009)The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use Respir Med 103 975-94

McCowan C(2005)Benefits of Omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 309-16

Neville RG(2010)Uniform definition of asthma severity, control and exacerbations: document presented for the World Health Organisation consultation on Severe Asthma J Allergy Clin Immunol 126 926-38

Thomas GE(2010)Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry Thorax 65 787-94

Smith B(1996)Exposure to house dust mite allergens and the clinical activity of asthma J Allergy Clin Immunol 98 64-72

Silverman S(1999)Sensitivity and exposure to indoor allergens in adults with differing asthma severity Eur Respir J 13 654-9

Manson SC(2003)Exposure and sensitisation to indoor allergens: Association with lung function, bronchial reactivity and exhaled nitric oxide measures in asthma J Allergy Clin Immunol 112 362-8

Brown RE(1997)The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma NEJM 336 1356-63

Holgate ST(2006)The mechanisms, diagnosis and management of severe asthma in adults Lancet 368 780-93

Polosa R(2000)Risk factors and costs associated with an asthma attack’ Thorax 55 19-24

Hoskins G(2009)The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use Respir Med 103 975-94

McCowan C(2005)Benefits of Omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 309-16

Neville RG(2010)Uniform definition of asthma severity, control and exacerbations: document presented for the World Health Organisation consultation on Severe Asthma J Allergy Clin Immunol 126 926-38

Thomas GE(2010)Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry Thorax 65 787-94

Smith B(1996)Exposure to house dust mite allergens and the clinical activity of asthma J Allergy Clin Immunol 98 64-72

Silverman S(1999)Sensitivity and exposure to indoor allergens in adults with differing asthma severity Eur Respir J 13 654-9

Manson SC(2003)Exposure and sensitisation to indoor allergens: Association with lung function, bronchial reactivity and exhaled nitric oxide measures in asthma J Allergy Clin Immunol 112 362-8

Brown RE(1997)The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma NEJM 336 1356-63